SeaCrest Wealth Management LLC Has $1.82 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

SeaCrest Wealth Management LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 21.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,167 shares of the company’s stock after purchasing an additional 3,083 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,819,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Cornerstone Planning Group LLC bought a new position in Novo Nordisk A/S during the second quarter worth about $29,000. Tower Research Capital LLC TRC raised its holdings in Novo Nordisk A/S by 165.3% in the first quarter. Tower Research Capital LLC TRC now owns 199 shares of the company’s stock worth $32,000 after purchasing an additional 124 shares during the period. Pacific Center for Financial Services boosted its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Valued Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $28,000. Finally, Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after acquiring an additional 141 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $0.35 on Thursday, reaching $128.40. The stock had a trading volume of 3,651,900 shares, compared to its average volume of 5,233,031. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The company has a market cap of $576.20 billion, a P/E ratio of 47.54, a price-to-earnings-growth ratio of 2.13 and a beta of 0.41. The firm has a fifty day moving average of $121.76 and a two-hundred day moving average of $104.38. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.35 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Investors of record on Monday, March 25th will be paid a $0.664 dividend. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, March 22nd. Novo Nordisk A/S’s payout ratio is 49.17%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, March 20th. TD Cowen boosted their price target on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, December 4th. UBS Group initiated coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $126.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.